Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of [123I] IMPY and SPECT as a Marker of Beta-amyloid Protein Deposition in the Brain of Healthy Subjects and Patients With Alzheimer Disease

NCT00287248 is registered in ClinicalTrials.gov with Institute for Neurodegenerative Disorders as lead sponsor.

NCT NCT00287248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00287248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of [123I] IMPY and SPECT as a Marker of Beta-amyloid Protein Deposition in the Brain of Healthy Subjects and Patients With Alzheimer Disease
Lead sponsor
Institute for Neurodegenerative Disorders
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2006
Completion date
March 31, 2008
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease